Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Benzoylaconitine and ginsenoside Rb1 synergistically attenuate cardiac remodeling through dual enhancement of DLG1-dependent mitochondrial integrity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Hao, Chen Qingshan, Zhang Qiqiang, Wang Liang, Di Xuemei, Nie Yonghong, Zhang Hai
Аннотация
BACKGROUND: The synergistic cardioprotective effects of monoester alkaloids and ginsenosides constitute the pharmacological basis of Shenfu decoction (SFD) for chronic heart failure. However, the underlying molecular interactions remain unclear.
PURPOSE: This study aimed to identify the key bioactive components of SFD, elucidate their molecular targets, and define the mechanistic pathways underlying their synergistic cardioprotective effects.
METHODS: We employed an ACE-dependent Ang I-stimulated cardiomyocyte hypertrophy model in vitro and a transverse aortic constriction (TAC) mouse model in vivo to evaluate pharmacological efficacy. Integrated transcriptomic-proteomic profiling identified downstream effectors, validated by genetic knockdown. The molecular targets were investigated using limited proteolysis-mass spectrometry (Lip-MS), molecular docking, surface plasmon resonance (SPR), cellular thermal shift assay (CETSA), and enzyme activity assays.
RESULTS: Benzoylaconitine (BAC) and ginsenoside Rb1 (Rb1) were identified as the dominant cardioprotective constituents of SFD. Pharmacological assessments demonstrated that BAC and Rb1 synergistically attenuated Ang Ⅰ-induced cardiomyocyte hypertrophy and fibrosis, and mitigated pathological cardiac remodeling in TAC mice. Integrated transcriptomic and proteomic analyses revealed that their combined treatment reduced mitochondrial reactive oxygen species (ROS) generation, suppressed mitochondrial fission, and restored mitochondrial homeostasis. Mechanistically, BAC promoted the transcription of Discs Large MAGUK Scaffold Protein 1 (DLG1), whereas Rb1 slowed its protein degradation, thereby synergistically upregulating DLG1 expression and improving mitochondrial function. Lip-MS further demonstrated that BAC specifically targeted angiotensin-converting enzyme (ACE) and inhibited its activity, whereas Rb1 targeted and activated ACE2, thereby rebalancing the renin-angiotensin-aldosterone system (RAAS) between the AT1R and MAS axes. This dual-target modulation ultimately contributed to the upregulation of DLG1, preserved mitochondrial integrity, and ameliorated maladaptive ventricular remodeling.
CONCLUSION: BAC and Rb1 exert synergistic cardioprotection by targeting ACE and ACE2, restoring RAAS homeostasis, enhancing DLG1 expression, and sustaining mitochondrial stability, thereby attenuating pathological cardiac remodeling. These findings highlight the potential of BAC and Rb1 as a dual-target synergistic therapy for heart failure.
PURPOSE: This study aimed to identify the key bioactive components of SFD, elucidate their molecular targets, and define the mechanistic pathways underlying their synergistic cardioprotective effects.
METHODS: We employed an ACE-dependent Ang I-stimulated cardiomyocyte hypertrophy model in vitro and a transverse aortic constriction (TAC) mouse model in vivo to evaluate pharmacological efficacy. Integrated transcriptomic-proteomic profiling identified downstream effectors, validated by genetic knockdown. The molecular targets were investigated using limited proteolysis-mass spectrometry (Lip-MS), molecular docking, surface plasmon resonance (SPR), cellular thermal shift assay (CETSA), and enzyme activity assays.
RESULTS: Benzoylaconitine (BAC) and ginsenoside Rb1 (Rb1) were identified as the dominant cardioprotective constituents of SFD. Pharmacological assessments demonstrated that BAC and Rb1 synergistically attenuated Ang Ⅰ-induced cardiomyocyte hypertrophy and fibrosis, and mitigated pathological cardiac remodeling in TAC mice. Integrated transcriptomic and proteomic analyses revealed that their combined treatment reduced mitochondrial reactive oxygen species (ROS) generation, suppressed mitochondrial fission, and restored mitochondrial homeostasis. Mechanistically, BAC promoted the transcription of Discs Large MAGUK Scaffold Protein 1 (DLG1), whereas Rb1 slowed its protein degradation, thereby synergistically upregulating DLG1 expression and improving mitochondrial function. Lip-MS further demonstrated that BAC specifically targeted angiotensin-converting enzyme (ACE) and inhibited its activity, whereas Rb1 targeted and activated ACE2, thereby rebalancing the renin-angiotensin-aldosterone system (RAAS) between the AT1R and MAS axes. This dual-target modulation ultimately contributed to the upregulation of DLG1, preserved mitochondrial integrity, and ameliorated maladaptive ventricular remodeling.
CONCLUSION: BAC and Rb1 exert synergistic cardioprotection by targeting ACE and ACE2, restoring RAAS homeostasis, enhancing DLG1 expression, and sustaining mitochondrial stability, thereby attenuating pathological cardiac remodeling. These findings highlight the potential of BAC and Rb1 as a dual-target synergistic therapy for heart failure.